Abstract
Introduction
Hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) is a rare monogenic disorder with autosomal dominant inheritance and an estimated prevalence of 1:10,000-50,000 in the general population. (1) Insufficient levels of functional complement component 1 inhibitor (C1-INH) lead to excessive levels of bradykinin, the main mediator of angioedema, thus the clinical picture is characterized by episodes of self-limiting, localized edema due to an increased vascular permeability, affecting different body sites, for instance, limbs, face, intestinal tract or airways. If not treated properly, laryngeal edema is associated with an extremely high risk of asphyxiation, and, consequently, death. (2) The disorder is caused by various mutations affecting the C1-INH gene -SERPING1 (OMIM*606860, C1I; C1INH SERPIN PEPTI-DASE INHIBITOR). (3, 4) HAE type I develops when C1-INH levels are reduced (85%), and type II in case of a dysfunctional C1-INH (15%). (5) The group with normal C1-INH (HAE-nC1-INH) comprises: HAE with mutation in F12 gene (HAE-FXII), HAE with mutation in the angiopoetin-1 gene (HAE-ANGPTI), HAE with mutation in the plasminogen gene (HAE-PLG), and HAE due to unknown mutations (HAE-UNK). (5) The SERPING1 gene is approximately 17 kb long, comprises 8 exons and 7 introns, and it is located in 11q12.1. It presents an unusual promoter with no TATA sequence but a TdT-like initiator and polypurine-polypyrimidine tract. (4) More than 450 distinct SERPING1 mutations associated with C1-INH HAE have been described to date, produced by various mechanisms, ranging from the most frequent point mutations causing missense, nonsense, splice site or frameshift mutations, to small and large insertions or deletions (HAEdb, http://www.hae.enzim.hu). (6) Allelic heterogeneity and the high frequency of de novo mutations in 20-25% of the cases are due to mutagenic liability. (6) Genetic complexity poses difficulties in patient management, from diagnosis and prognosis assessment to the choice of optimal treatment. Ethnic differences have been shown to be important, and may influence disease manifestations, severity and progression.(7) Studies analyzing genoand phenotype correlations with potential predictive value are limited, and the results are controversial. (7) (8) (9) (10) (11) Based on these considerations, we proposed to analyze the clinical and genetic characteristics in a set of patients, intended for a more tailored management of C1-INH-HAE affected Romanian families.
Material and Methods
Forty-nine patients from 22 unrelated families with C1-INH-HAE were included in the study, recruited through the Romanian Registry of Hereditary Angioedema (www.haenet.ro). Diagnosis of C1-INH-HAE was based on family and/or personal history of recurrent angioedema without urticaria associated with antigenic and/or functional C1-INH deficiency. Serum concentrations of C1-INH and C4 were quantified using nephelometric assays (BN Prospec, Siemens Healthcare GmbH), while functional C1-INH was measured by functional enzyme-linked immunosorbent assay (MicroVue functional C1-inhibitor, Quidel Corporation) on automated ELISA analyser (Adaltis, Italy). Clinical severity score was calculated using the age of onset, number of organs affected and long-term prophylaxis, and expressed from 0 to 10, as proposed by Bygum et al. (8) Peripheral venous blood samples were collected from 28 patients, 22 index cases and 6 first degree relatives exhibiting the disease, and sent to the Department of Immunology & Histocompatibility School of Medicine, University of Thessaly for genetic analysis. Genomic DNA was isolated, and SERPING1 mutations were detected by sequencing after PCR amplification of all exons and exon/intron boundaries, followed by long-range PCR and MLPA for the identification of large rearrangements in 28 cases, as published previously. (7) In symptomatic first degree relatives with a clinical diagnosis but no molecular analysis of index cases with a known mutation, the presence of the same mutation was considered. The study was carried out in accordance with the Principles of the Declaration of Helsinki and a written informed consent was obtained from the patients. Results were expressed as mean, standard deviation, and percentage. To test genotype -phenotype associations on the index cases sample, the Chi-square and Mann-Whitney tests were applied for categorical and continuous variables, respectively. Genotype-phenotype associations in the extended sample including family members were explored using the complex sample Chi-square test and complex sample student t test for categorical and continuous variables respectively, with controlling for the intracluster correlations due to patient aggregation at family level in SPSS v. 22.0.(12,13) A two-tailed p-value of less than 0.05 was considered statistically significant.
Results
Twenty-two index cases and a total of 49 patients from the twenty two unrelated families with HAE type I and II were included in the study. The study population included 25 To address possible geno-and phenotype correlations, clinical data was compared according to the type of mutation, patients being classified in two groups based on the presence of missense mutations (group 1), or any other mutation mechanisms (group 2), as seen in Table II . A tendency of less severe clinical manifestations was noted dependent on the mutation mechanism, in the presence of missense mutations leading to the substitution of a single aminoacid as compared (Figure 3 ).
Discussion
In an effort to further our understanding of the disorder and improve patient management, Beyond the scientific value, mutation analysis of our patients significantly helped the management of affected families, by confirmation of diagnosis and identification of mutation carrier relatives, 53% of our cases having been identified by familial screening. It has been reported that 5% of adult cases are identified only after a child is diagnosed in the family, and approximately 14% of mutation carriers remain asymptomatic throughout their life,(6,7) which was not the case in our patients.
Interpretation of mutation analysis is burdened by important allelic heterogeneity with over 450 mutations described so far in the SERPING1 gene. Moreover, various polymorphisms must be differentiated from causative mutations using limited approaches, like segregation analysis or functional studies. The high mutation rate is explained by the position of the gene locus situated close to the centromere, in a region with high Alu repeat content and CpG sites. (18, 19) In our investigated cohort, 87.75% were familial and 12.25% appeared as sporadic cases, suggesting de novo mutations. Family history was positive in approximately 2/3 of the unrelated index cases, comparable to 20-25% described in the literature. (20) The high frequency of newly described mutations makes simple analytical methods less applicable and the use of conventional investigational approaches is considered to be fraught with pitfalls (e.g. identification of novel missense mutations may prevent the description of indel mutations leading to truncated proteins or deep intronic mutations affecting splicing). (6,7,21) Thus sequencing is necessary, which usually targets exon sequences and exon-intron boundaries, and is combined with long-range PCR and MLPA (multiplex ligation-dependent probe amplification) for the assessment of large rearrangements, as it was done also in our patients.(7) Recent analytical developments may further improve existing diagnostic possibilities. Targeted next-generation sequencing can provide the necessary analytical sensitivity, and is currently recommended for implementation as a first line approach for genetic testing, or as a confirmatory technique.(21) Important ethnic differences have been noticed regarding the mutation mechanisms. (7) Epigenetic influences and regional environmental factors like diet or radiation are quoted to be responsible for the mutation profile different in various countries. (7) Compared with recent publications and current SERPING1 mutation database data, the mutation mechanism in Romanian patients shows an unusual distribution, (7, 10, 22, 23) confirming previous reports now on a larger group of cases, with a significantly greater proportion of missense mutations and splice defects (61.22% and 22.4%, respectively), a lower frequency of nonsense and frameshift mutations, as well as large gene rearrangements than in other populations; no mutations were described in the regulatory sequence. Novel mutations described in Romanian patients include c.122delG, c.650_651del-GT (frameshift mutations), c.124G>T (nonsense mutation), c.498C>A -N166K (missense mutation) , c.889+4delAGGGT (splice defect), as published previously. (7 (1, (34) (35) (36) . In 70% of the cases, these mutations are situated in exon 8, a functionally critical region encoding the reactive site in serpins, especially Arg444 (or Arg466). Pathogenic missense mutations were found in ¾ of the unrelated Romanian index cases presenting HAE type I, and 100% of type II patients, situated exclusively in exon 8. In heterozygous patients, the unusually markedly reduced C1-INH levels to 5-30% of the normal level is suspected to be related to an increased catabolic rate and reduced synthesis with the down-regulation of the normal allele, a possible dominant negative effect, though as of now it remains insufficiently explained. (19, 37, 38) Inter-and intrafamilial variable clinical expressivity, as suggested also by the changeable age of onset in the represented family tree ( Figure  3 ), may be related to genetic and non-genetic factors. Various factors like SERPING1 gene polymorphisms (e.g. rs4926, rs28362944) and mutations in other genes (e.g. C4B, BDKR 1 and 2, MBL2, ACE) were studied as potential modifiers. (6) The -46C/T polymorphism in the F12 gene promoter sequence (rs1801020) appeared to correlate consistently with disease severity, as reported previously in a study also including a set of Romanian patients. (7) Given the characteristic later manifestation in Romanian patients, the presence of the G allele of the KLKB1-Ser143Asn polymorphism investigated in a subset of 19 patients was reported to appear as an independent genetic factor correlated with a delayed onset in C1-INH HAE. (39) Based on previous observations,(7) in order to investigate genotype-phenotype associations, we separated patients in two groups carrying the frequent missense mutations with presumably less severe changes in gene product structure, and nonsense, splice, frameshift mutations, insertions and deletions of variable sizes producing a more severe effect on C1-INH level and function. Comparison of severity and clinical manifestations demonstrated that according to the presumed effect on gene product stability dependent on mutation mechanism, there was a more severe reduction of C1-INH level in carriers of other than missense mutations as also noted by other authors, (7) (8) (9) (10) (11) which reached the level of statistical significance, but only in probands (p=0.017 vs 0.116). With marked variations in each group, neither the age of onset nor the calculated score denoting clinical severity demonstrated significant differences. Interpretation of our current results remains, however, limited by the relatively low number of cases, and insufficient genetic investigations, analysis of modifying genetic factors. It will be interesting to see how the currently developed global HAE registry data with more statistical power will clarify the tendencies noted in our cohort.
Conclusion
A later onset of disease manifestations and a higher frequency of missense mutations characterize HAE in Romanian patients with SER-PING1 mutation. Genetic analysis provides information necessary for the optimization of management in the affected family, assisting the clarification of diagnosis in affected relatives. Lower levels of C1-INH may characterize mutations caused by mechanisms other than the substitution of a single aminoacid. In Romanian patients with HAE type II, exclusively missense mutations were noted.
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